Medable launched its new vaccine offering, providing the industry with the speed, ease, and expertise needed to launch vaccine studies in as little as 5 weeks.
Musaddiq Khan, VP of DCT Solutions, explains the cross collaborative effort taken to create this new offering, its benefits, and why hybrid/decentralized solutions are the perfect fit for vaccine trials.
Download the full article here.
Musaddiq is a VP, DCT Solutions, Vaccines, Infectious Diseases & Respiratory at Medable.
